Results 11 to 20 of about 27,148 (204)

Radiopharmaceutical Validation for Clinical Use [PDF]

, 2021
Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation.
Capala, Jacek, Myint, Zin W., Howells, Rodney, Chauhan, Aman, Kunos, Charles A., El Khouli, Riham H., Bernard, Mark E., Zin W. Myint, Riham El Khouli, Mark E. Bernard, Aman Chauhan, Charles A. Kunos, Rodney Howells, Jacek Capala   +13 more
core   +1 more source

Regulation of Radiopharmaceutical Products [PDF]

, 2022
The fast development of diagnostic and therapeutic radionuclide technologies requires enhanced legislative regulation of radiopharmaceuticals. The article addresses the challenge of classifying radiopharmaceuticals depending on the manufacturing ...
A. A. Trapkova, S. N. Kalmykov, V. V. Kosenko   +2 more
core   +1 more source

Binding Parameters of [¹¹C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents

, 2023
Impairment and/or destabilization of neuronal microtubules (MTs) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including Alzheimer’s disease (AD), Parkinson’s disease and other neurological disorders ...
Naresh Damuka, Ivan Krizan, Mack Miller, Suzanne Craft, Akiva Mintz, Krishna Kumar Gollapelli, Avinash H. Bansode, Bhuvanachandra Bhoopal, Kiran Kumar Solingapuram Sai   +8 more
core   +1 more source

[⁶⁸Ga]Ga-PSMA-11: The First FDA-Approved ⁶⁸Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

, 2021
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in
Matthias Eder, Ute Hennrich, Eder, Matthias, Hennrich, Ute   +3 more
core   +1 more source

Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer

, 2020
Financial toxicity or the debt a cancer survivor incurs from the costs of their medical cancer care is an understudied aspect in the clinical development of experimental therapeutic agents. The United States National Cancer Institute (NCI) Cancer Therapy
Rita Abdallah, Charles A. Kunos
core   +1 more source

Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma

, 2020
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI ...
Charles Kunos, Jacek Capala, Charles A. Kunos   +2 more
core   +1 more source

Simultaneous Visualization of ¹⁶¹Tb- and ¹⁷⁷Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

Pharmaceutics, 2021
The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes.
Francesca Borgna, Patrick Barritt, Pascal V. Grundler, Zeynep Talip, Susan Cohrs, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller   +9 more
doaj   +1 more source

Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files

Frontiers in Oncology, 2019
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity.
Charles A. Kunos, Jacek Capala, Susan Percy Ivy   +2 more
doaj   +1 more source

Improved accuracy of S-value-based dosimetry: a guide to transition from Cristy–Eckerman to ICRP adult phantoms

EJNMMI Physics, 2022
Background In 2016, the International Commission on Radiological Protection (ICRP) published the results of Monte Carlo simulations performed using updated and anatomically realistic voxelized phantoms. The resulting specific absorbed fractions are based
Shalini Subramanian, Bin He, Eric Frey, Derek W. Jokisch, Wesley Bolch, George Sgouros   +5 more
doaj   +1 more source

The Use of Low Ammonia Concentration in the Radiochemical Purity Test of [153Sm]Sm-EDTMP by Using the Thin Layer Chromatography Method [PDF]

Journal of Pure and Applied Chemistry Research, 2021
Radiochemical purity testing of [153Sm]Sm-EDTMP usually uses the Thin Layer Chromatography method. The mobile phase used is a mixture of 25% ammonia and water. However, the lowest ratio of 25% ammonia in the mobile phase is unknown.
Amal Rezka Putra, Khoirunnisa Fauziah Asyikin, Robertus Dwi Hendarto, Agus Ariyanto, Enny Lestari, Sumandi Juliyanto, Ahsanal Fikri   +6 more
doaj